Identification of a potent new chemotype for the selective inhibition of PDE4
- 15 February 2008
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (4), 1297-1303
- https://doi.org/10.1016/j.bmcl.2008.01.028
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Novel 5,6-dihydropyrazolo-[3,4-E][1,4]diazepin-4 (1H)-one derivatives for the treatment of asthma and chronic obstructive pulmonary diseaseExpert Opinion on Therapeutic Patents, 2007
- Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel diseaseExpert Opinion on Investigational Drugs, 2007
- Anxiogenic-Like Behavioral Phenotype of Mice Deficient in Phosphodiesterase 4B (PDE4B)Neuropsychopharmacology, 2007
- Rolipram: A specific phosphodiesterase 4 inhibitor with potential antipsychotic activityNeuroscience, 2007
- Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilastExpert Opinion on Investigational Drugs, 2006
- Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory diseaseExpert Opinion on Investigational Drugs, 2006
- Phosphodiesterase-4 as a potential drug targetEmerging Therapeutic Targets, 2005
- Cyclic nucleotide research — still expanding after half a centuryNature Reviews Molecular Cell Biology, 2002
- The effect of selective and non‐selective phosphodiesterase inhibitors on allergen‐ and leukotriene C4‐induced contractions in passively sensitized human airwaysBritish Journal of Pharmacology, 2000
- Suppression of human inflammatory cell function by subtype‐selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4BBritish Journal of Pharmacology, 1999